NSE · Equity shares · Crops

Nath Bio-Genes (India) Ltd NATHBIOGEN

NSE:INR 147.0118 Sept, 03:29 pm

BSE:INR 14818 Sept, 03:29 pm

-1.13 · -0.76%

Advanced chart

Data quality and coveragePrice, company fundamentals and optional research feeds are tracked separately.

Headline priceLast market snapshot18 Sept, 03:29 pm

Company fundamentalsStale · last-known data22 Jul, 01:15 pm

Research sections8 of 9 availableMissing source values remain unavailable, never zero-filled.

AI and Advanced

AI analysis and Advanced tools for NATHBIOGEN

Analysis, reports, chat and Advanced access use the same Rusaka Markets account. The backend remains authoritative for roles, subscriptions, credits and permissions.

AI analysisReview the complete evidence-led AI research workflow.Generate reportCreate a versioned report with entitlement and credit checks.Open AI ChatContinue a grounded conversation with the instrument in context.Advanced modulesOpen role- and entitlement-controlled portfolio and trading tools.

Snapshot

Price and key statistics

Reported and computed values remain separate; missing values are not converted to zero.

Previous closeINR 148.14

Day rangeINR 145 — INR 149.08

52-week rangeINR 126.15 — INR 207

Volume2,609

Market cap311.58

P/ENot available

Fundamental highlightsReported values unless marked as computed

Revenue (INR Cr)445.1

Net Income (INR Cr)41.63

EPS18.26

Research path: Interpret Nath Bio-Genes (India) Ltd's snapshot alongside the wider market dashboard, the financial-statement research guide and the valuation-ratios field guide.

Validated OHLC

Interactive price chart

Crosshair, OHLCV tooltip, indicators, volume, zoom and pan use the same candle API as the advanced workspace.

Open full workspace

NATHBIOGENNath Bio-Genes (India) Ltd1d · INR · NSE

Loading validated candles…

Resolution: 1d nativeOHLC validation passed0 candles loadedWheel: zoom · Shift+wheel: pan

Auditable calculations

Daily technical summary

Calculated from validated daily candles. Descriptive research only.

Calculating technicals…

Indicators describe price behaviour and volatility; they are not a BUY, NEUTRAL or SELL recommendation.

Company reporting

Financial statements

IND AS · INR crore

Metric	2026	2025	2024
Total Liabilities Shareholders' Equity	1,097.42	1,026.21	880.23
Cash Equivalents	76	87.05	74.01
Other Liabilities Total	4.95	3.54	3
Long Term Debt	17.32	11.37	2.04
Common Stock Total	19	19	19
Other Current Assets Total	2.5	0.37	Not available
Total Assets	1,097.42	1,026.21	880.23
Current Portof LT Debt/Capital Leases	121.18	1.38	1.35
Total Equity	680.46	644.39	609.92
Long Term Investments	26.51	5.78	6.05
Retained Earnings(Accumulated Deficit)	661.45	491.88	457.08
Total Common Shares Outstanding	1.9	1.9	1.9
Tangible Book Valueper Share Common Eq	355.12	335.3	316.31
Total Liabilities	416.96	381.82	270.31
Total Debt	138.5	122.5	110.35
Short Term Investments	163.42	0.01	0.01
Cashand Short Term Investments	239.42	88.53	77.41
Total Receivables Net	86.39	98.69	102.11
Accounts Receivable-Trade Net	85.41	90.41	94.31
Property/Plant/Equipment Total-Net	243.82	243.19	240.65
Total Current Liabilities	394.7	365.3	262.45
Total Inventory	450.55	501.99	391.86
Accounts Payable	131.12	79.48	43.3
Other Currentliabilities Total	142.4	164.47	113.67
Total Long Term Debt	17.32	12.98	4.87
Intangibles Net	5.59	7.18	8.81
Other Long Term Assets Total	42.64	1.29	1.28
Total Current Assets	778.86	690.01	571.66
Accumulated Depreciation Total	Not available	-19.71	-17.53
Accrued Expenses	Not available	11.83	Not available
Other Equity Total	Not available	0	0.33
Prepaid Expenses	Not available	0.43	0.29
Additional Paid-In Capital	Not available	133.5	133.5
Cash	Not available	1.48	3.39
Property/Plant/Equipment Total-Gross	Not available	262.91	258.18
Notes Payable/Short Term Debt	Not available	108.14	104.13
Note Receivable-Long Term	Not available	78.76	51.78
Capital Lease Obligations	Not available	1.61	2.83

Fundamentals

Valuation and ratios

Valuation

Price to Sale Ratio0.70

Risk and consensus

Source-qualified signals

Risk metrics

Overall RiskBalanced risk

Board Risk43.19

Analyst consensus

Analyst consensus unavailable.

Provider consensus uses a 1 (Strong Buy) to 5 (Strong Sell) score. The payload does not include price targets, so none are inferred from 52-week prices or recommendation percentages.

Industry context

Peer comparison

Only peers present in the company profile payload are displayed.

Peer data unavailable in the company profile payload.

Shareholding

Ownership

Promoter: 45.60%
FII: 0.26%
MF: 0.01%
Other: 54.13%

Company intelligence

Latest relevant news

Source, timestamp and external destination are shown. Provider relevance scores are not available.

Nath Bio-Genes (India) Ltd is Rated Sell - Markets MojoMarket news · 3 Jun 2026, 2:34 am

Nath Bio-Genes (India) Ltd is Rated Sell Markets Mojo

Nath Bio-Genes (India) Ltd Upgraded to Hold on Technical and Valuation Improvements - Markets MojoMarket news · 2 Jun 2026, 3:07 pm

Nath Bio-Genes (India) Ltd Upgraded to Hold on Technical and Valuation Improvements Markets Mojo

Golden Cross Confirmed: Do Nath Bio-Genes' Other Technical Indicators Agree? - Markets MojoMarket news · 1 Jun 2026, 6:07 pm

Golden Cross Confirmed: Do Nath Bio-Genes' Other Technical Indicators Agree? Markets Mojo

Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvement Despite Weak Fundamentals - Markets MojoMarket news · 27 May 2026, 4:48 am

Nath Bio-Genes (India) Ltd Upgraded to Sell on Technical Improvement Despite Weak Fundamentals Markets Mojo

Nath Bio-Genes (India) Ltd is Rated Strong Sell - Markets MojoMarket news · 25 May 2026, 5:09 am

Nath Bio-Genes (India) Ltd is Rated Strong Sell Markets Mojo

Nath Bio-Genes Q4 FY26 Earnings Call: Revenue Up 19%, Audio Recording Submitted - scanx.tradeMarket news · 11 May 2026, 12:30 pm

Nath Bio-Genes Q4 FY26 Earnings Call: Revenue Up 19%, Audio Recording Submitted scanx.trade

Corporate actions

Events

2026-07-29board MeetingsQuarterly Results
2026-05-04dividendRs.2.0000 per share(20%)Final Dividend
2026-05-04board MeetingsAudited Results & Final Dividend
2026-01-31board MeetingsQuarterly Results
2025-11-13board MeetingsQuarterly Results
2025-08-22annual General MeetingAGM
2025-08-14dividendRs.2.0000 per share(20%)Final Dividend
2025-07-11board MeetingsQuarterly Results

Rusaka Markets Community

Discussion and sentiment for Nath Bio-Genes (India) Ltd

Posts are linked to the canonical company record. Community BUY, NEUTRAL and SELL opinions are user-generated, moderated and separate from analyst consensus and Rusaka Markets AI.

Checking your Rusaka Markets account…

Company profile

Business information

What the company does

Not available

Company facts

Industry: Crops
Sector: Crops
NSE Code: NATHBIOGEN
BSE Code: 537291

Questions

Stock FAQ

What is the symbol and ISIN of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd has the symbol NATHBIOGEN and ISIN - INE448G01010.

What is the current price of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd is currently trading at INR 147.01.

What are the year high and year low of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd has a year high of INR 207.00 and a year low of INR 126.15.

What is the market capitalization of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd has a market capitalization of INR 311.58 crore.

What is the P/E ratio of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd has a P/E ratio of NA.

What is the dividend yield of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd has a dividend yield of NA.

How is the financial performance of Nath Bio-Genes (India) Ltd based on revenue, net income, and EPS?

Nath Bio-Genes (India) Ltd has revenue of INR 445.10 crore, net income of INR 41.63 crore, and EPS of NA.

What is the book value of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd has a book value of NA.

What is the debt-to-equity ratio of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd has a debt-to-equity ratio of NA.

What are the price-to-book and price-to-sales ratios of Nath Bio-Genes (India) Ltd?

Nath Bio-Genes (India) Ltd has a price-to-book ratio of NA and a price-to-sales ratio of 0.70.

Corporate-action adjustment is provider-defined. Rusaka Markets research and computed indicators are not investment advice.